KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Change in Receivables (2016 - 2025)

Abbott Laboratories (ABT) has disclosed Change in Receivables for 17 consecutive years, with -$222.0 million as the latest value for Q4 2025.

  • Quarterly Change in Receivables fell 240.51% to -$222.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $652.0 million through Dec 2025, down 5.64% year-over-year, with the annual reading at $652.0 million for FY2025, 5.64% down from the prior year.
  • Change in Receivables hit -$222.0 million in Q4 2025 for Abbott Laboratories, down from $202.0 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $751.0 million in Q1 2022 to a low of -$530.0 million in Q3 2022.
  • Historically, Change in Receivables has averaged $107.5 million across 5 years, with a median of $173.0 million in 2022.
  • Biggest YoY gain for Change in Receivables was 637.14% in 2022; the steepest drop was 280.42% in 2022.
  • Year by year, Change in Receivables stood at $189.0 million in 2021, then tumbled by 280.42% to -$341.0 million in 2022, then surged by 80.06% to -$68.0 million in 2023, then skyrocketed by 332.35% to $158.0 million in 2024, then tumbled by 240.51% to -$222.0 million in 2025.
  • Business Quant data shows Change in Receivables for ABT at -$222.0 million in Q4 2025, $202.0 million in Q3 2025, and $410.0 million in Q2 2025.